Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Short Interest Up 161.0% in July

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 467,461 shares, an increase of 161.0% from the July 15th total of 179,105 shares. Based on an average trading volume of 2,318,553 shares, the short-interest ratio is currently 0.2 days. Currently, 4.2% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. acquired a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned about 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent quarter.

Hong Kong Pharma Digital Technology Price Performance

NASDAQ HKPD traded down $0.00 during trading hours on Friday, hitting $0.42. 70,857 shares of the company were exchanged, compared to its average volume of 1,286,853. The company has a 50 day moving average of $0.41 and a two-hundred day moving average of $0.57. Hong Kong Pharma Digital Technology has a 52-week low of $0.31 and a 52-week high of $2.58.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $3.15 million during the quarter.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.